Modality: RNA Therapy Clinical Trials Market by Modality: The RNA therapy clinical trials market can be segmented by modality into oligonucleotide-based therapies and mRNA-based therapies. Oligonucleotide-based therapies involve the use of short DNA or RNA molecules to target specific genes or proteins in the body, while mRNA-based therapies utilize messenger RNA to instruct cells to produce therapeutic proteins. Both modalities show promising results in various therapeutic areas, driving the growth of the RNA therapy clinical trials market. Phase: RNA Therapy Clinical Trials Market by Phase: The RNA therapy clinical trials market can also be segmented by phase into phase I, phase II, and phase III clinical trials. Phase I trials focus on the safety and dosage of RNA therapies in a small group of patients, while phase II trials evaluate the efficacy and side effects in a larger group. Phase III trials further confirm the safety and efficacy of RNA therapies in a larger patient population. The different phases of clinical trials play a crucial role in determining the success and market approval of RNA therapies. Therapeutic Areas: RNA Therapy Clinical Trials Market by Therapeutic Areas: The RNA therapy clinical trials market can be categorized into rare diseases, anti-infective, anticancer, and neurological therapeutic areas. RNA therapies show great promise in treating rare diseases by targeting specific genetic mutations, providing hope for patients with rare and often incurable conditions. In the anti-infective therapeutic area, RNA therapies hold potential for developing novel treatments for infectious diseases by targeting the genetic material of pathogens. Anticancer RNA therapies target cancer cells with precision, offering new treatment options for cancer patients. In the neurological therapeutic area, RNA therapies show potential for treating neurodegenerative disorders by targeting specific genes involved in disease progression. The diverse therapeutic areas supported by RNA therapies highlight the versatility and broad applicability of this emerging treatment modality in clinical trials.